Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
Eligibility criteria
Qualifiers
Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma；
recurrent HCC without any tumor related therapy；
Tumor number ≤3；
Tumor size ≤5cm;
Disqualifiers
disagreeing to receive follow-up observation and participate the clinical study;
Accompanying with a history of other malignancies;
Accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus;
with extrahepatic metastasis or lymph metastasis;
Trial design
Treatments tested in this trial
- Microwave ablation
- Lenvatinib
Treatment groups
274 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov